|
1) Sugitani A, Kitada H, Ota M, et al. Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transplant. 2006; 20: 590-5
|
|
|
|
2) Yoshioka K, Ohashi Y, Sakai T, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000; 58: 317-24
|
|
|
|
|
|
3) Tanaka H, Suzuki K, Nakahata T, et al. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin Nephrol. 2003; 60: 390-4
|
|
|
|
|
|
4) Tanaka H, Tsugawa K, Suzuki K, et al. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis. Pediatr Nephrol. 2006; 21: 962-6
|
|
|
|
|
|
5) 上村 治, 牛嶌克実, 金原有里, 他. 小児腎疾患におけるミゾリビンの至適投与量 ステロイド依存性ネフローゼ症候群に対して5mg/kg/dayは少なすぎる？ 日児腎誌. 2005; 18 Suppl: 116
|
|
|
|
|
|
6) 上村 治, 牛嶌克実, 山田拓司, 他. 小児におけるミゾリビン内服時の血中濃度および尿中排泄量の検討 ?bio-availabilityは年齢によって変化する?. 日児腎誌. 2007; 20: 9-13
|
|
|
|
|
|
7) 蕨 治言, 阿部重人, 近藤啓文. 慢性関節リウマチ患者におけるミゾリビン連続投与時の体内動態. リウマチ科. 1991; 5: 287-300
|
|
|
|
|
8) 阿部祥英, 関真由美, 中田雅之, 他. 小児期発症腎疾患におけるミゾリビンの体内動態に関する検討. 日児腎誌. 2004; 17: 85-9
|
|
|
|
|
|
9) 阿部祥英, 宮沢篤生, 三川武志, 他. 小児期発症腎疾患患児における低用量および高容量ミゾリビンの薬物動態に関する比較検討. 日児腎誌. 2005; 18: 91-6
|
|
|
|
|
|
10) Hamasaki T, Mori M, Kinoshita Y, et al. Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr Nephrol. 1997; 11: 625-7
|
|
|
|
|
|
11) Ohtomo Y, Fujinaga S, Takada M, et al. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005; 20: 1744-9
|
|
|
|
|
|
12) 後藤美和, 池田昌弘, 幡谷浩史, 他. 小児頻回再発型ネフローゼ症候群に対するミゾリビン高用量治療の再発抑制効果と安全性. 日腎会誌. 2006; 48: 365-70
|
|
|
|
|
|
13) Kawasaki Y, Takano K, Isome M, et al. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007; 20: 52-6
|
|
|
|
|
|
14) Ginzler EM, Dooley MA, Aranow C, et al. Myco-phenolate mofetil or intravenous cyclophospha-mide for lupus nephritis. N Engl J Med. 2005; 353: 2219-28
|
|
|
|
|
|
15) Tanaka H, Tsugawa K, Nakahata T, et al. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol. 2005; 63: 417-22
|
|
|
|
|
|
16) Hayashi A, Hanada T, Kohda T, et al. Mizoribine oral pulse therapy for a patient with polyarticular juvenile idiopathic arthritis. Pediatr Int. 2006; 48: 638-40
|
|
|
|
|
|
17) Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int. 2002; 44: 205-9
|
|
|
|
|
|
18) Stypinski D, Obaidi M, Combs M, et al. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol. 2007; 63: 459-68
|
|
|
|
|
|
19) Takahashi S, Wakui H, Gustafsson JA, et al. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000; 274: 87-92
|
|
|
|
|
|
20) Liu D, Kobayashi T, Nagasaka T, et al. Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. Transpl Int. 2007; 20: 365-70
|
|
|
|
|
|
21) 村瀬潤一, 水野公雄, 川井邦男, 他. Bredininのラットにおける吸収, 分布, 代謝および排泄. 応用薬理. 1978; 15: 829-35
|
|
|
|
|
|
22) Okada M, Suzuki K, Nakashima M, et al. The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats. Eur J Pharmacol. 2006; 15: 140-4
|
|
|
|
|
|
23) Ritzel MW, Yao SY, Ng AM, et al. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na＋/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol. 1998; 15: 203-11
|
|
|
|
|